SRDX - Surmodics Inc Stock Price, Fair Value and News

$39.75-0.16 (-0.40%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SRDX Price Action

Last 7 days

-0.7%

Last 30 days

1.5%

Last 90 days

1.3%

Trailing 12 Months

9.4%

SRDX RSI Chart

SRDX Valuation

Market Cap

569.5M

Price/Earnings (Trailing)

-49.34

Price/Sales (Trailing)

4.52

EV/EBITDA

132.98

Price/Free Cashflow

-175.54

SRDX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SRDX Fundamentals

SRDX Revenue

Revenue (TTM)

126.1M

Rev. Growth (Yr)

18.8%

Rev. Growth (Qtr)

9.51%

SRDX Earnings

Earnings (TTM)

-11.5M

Earnings Growth (Yr)

-151.52%

Earnings Growth (Qtr)

54.34%

SRDX Profitability

EBT Margin

-5.95%

Return on Equity

-9.71%

Return on Assets

-6.46%

Free Cashflow Yield

-0.57%

SRDX Investor Care

Shares Dilution (1Y)

1.20%

Diluted EPS (TTM)

-0.82

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	143.0M	120.8M	126.1M	0
2023	103.0M	130.6M	132.6M	138.2M
2022	97.0M	97.9M	100.0M	101.9M
2021	106.7M	103.7M	105.1M	105.8M
2020	100.6M	103.1M	94.9M	94.5M
2019	90.2M	92.3M	100.1M	100.5M
2018	73.9M	78.4M	81.3M	86.6M
2017	73.4M	71.2M	73.1M	72.4M
2016	66.5M	70.6M	71.4M	72.6M
2015	58.6M	59.9M	61.9M	64.2M
2014	56.1M	56.4M	57.4M	57.8M
2013	56.1M	56.1M	56.1M	56.2M
2012	54.4M	55.7M	56.1M	56.1M
2011	53.6M	53.2M	52.8M	54.1M
2010	0	88.0M	54.5M	54.1M
2009	0	0	121.5M	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Surmodics Inc

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

CEO	Mr. Gary R. Maharaj
WEBSITE	surmodics.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	447

Surmodics Inc Frequently Asked Questions

What is the ticker symbol for Surmodics Inc? What does SRDX stand for in stocks?

SRDX is the stock ticker symbol of Surmodics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Surmodics Inc (SRDX)?

As of Fri Dec 20 2024, market cap of Surmodics Inc is 569.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SRDX stock?

You can check SRDX's fair value in chart for subscribers.

Is Surmodics Inc a good stock to buy?

The fair value guage provides a quick view whether SRDX is over valued or under valued. Whether Surmodics Inc is cheap or expensive depends on the assumptions which impact Surmodics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SRDX.

What is Surmodics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, SRDX's PE ratio (Price to Earnings) is -49.34 and Price to Sales (PS) ratio is 4.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRDX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Surmodics Inc's stock?

In the past 10 years, Surmodics Inc has provided 0.062 (multiply by 100 for percentage) rate of return.